SIGMAR1 and depressive disorder: The results obtained in vitro correspond to the neuroprotective effect of Sigma1R agonists in modeling Parkinson’s disease in vivo [261,262] and the effectiveness of MAO-B inhibitors in comorbid depressive disorders [263].